Beyond Glycemic Control: GLP-1 Receptor Agonists and Their Impact on Calcium Homeostasis in Real-World Patients.
超越血糖控制:GLP-1 受體激動劑及其對真實世界患者鈣穩態的影響。
J Clin Med 2024-08-29
Narrative Review of Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Health in People Living with Obesity.
肥胖患者中胰高血糖素樣肽-1受體激動劑對骨骼健康影響的敘述性回顧。
Calcif Tissue Int 2024-03-08
Glucagon-like Peptide-1 Receptor Agonists and Diabetic Osteopathy: Another Positive Effect of Incretines? A 12 Months Longitudinal Study.
胰高血糖素樣肽-1受體激動劑與糖尿病性骨病:胰高血糖素樣激素的另一個正面效應?一項為期12個月的縱向研究。
Calcif Tissue Int 2024-06-12
Pharmacovigilance study of GLP-1 receptor agonists for metabolic and nutritional adverse events.
GLP-1 受體激動劑在代謝和營養不良事件的藥物監測研究。
Front Pharmacol 2024-07-23
EXPRESS: Glucagon-Like Peptide-1 Receptor Agonist Therapy Effects on Glycemic Control and Weight in a Primary Care Clinic Population.
EXPRESS: Glucagon-Like Peptide-1 受體激動劑療法對初級保健診所人群的血糖控制和體重影響。
J Investig Med 2024-07-30
Correlation Study of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) on Diabetic Patients with Hypertension.
GLP-1 受體激動劑 (GLP-1RAs) 與高血壓糖尿病患者之間的相關性研究。
Iran J Public Health 2024-08-01
Clinical Outcomes of Tirzepatide or GLP-1 Receptor Agonists in Individuals With Type 2 Diabetes.
Tirzepatide 或 GLP-1 受體激動劑在 2 型糖尿病患者中的臨床結果。
JAMA Netw Open 2024-08-12
Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study.
肥胖且無第二型糖尿病個體中,胰高血糖素樣肽-1受體激動劑的長期安全性和療效:一項全球回顧性隊列研究。
Diabetes Obes Metab 2024-08-22
The Effect of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists on the Lipid Profile of Diabetic Patients Using Statins: A Retrospective Cohort Study in the Diabetic Center of King Salman Bin Abdulaziz Hospital, Saudi Arabia.
GLP-1 受體激動劑對使用他汀類藥物的糖尿病患者脂質譜的影響:沙烏地阿拉伯 King Salman Bin Abdulaziz 醫院糖尿病中心的回顧性隊列研究。
Cureus 2024-08-27
Mortality and Serious Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System.
與胰高血糖素樣肽-1受體激動劑相關的死亡率和嚴重不良事件:使用FDA不良事件報告系統的藥物監測研究。
Cureus 2024-09-02